Drug Profile


Alternative Names: Dismutec; PEG-SOD; PEG-superoxide dismutase; Polyethylene glycol superoxide dismutase; WIN 22118

Latest Information Update: 26 Aug 2002

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Enzon Pharmaceuticals
  • Class Oxidoreductases; Polyethylene glycols
  • Mechanism of Action Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Craniocerebral trauma; Reperfusion injury; Stroke

Most Recent Events

  • 11 Jul 1997 Discontinued - Clinical trials for Stroke (unspecified route)
  • 08 Jul 1997 Sanofi Winthrop is no longer a licensee for pegorgotein
  • 08 Jul 1997 Discontinued-III for Head injuries in France (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top